Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial
Berry-Kravis, Elizabeth M., Harnett, Mark D., Reines, Scott A., Reese, Melody A., Ethridge, Lauren E., Outterson, Abigail H., Michalak, Claire, Furman, Jeremiah, Gurney, Mark E.
Published in Nature medicine (01.05.2021)
Published in Nature medicine (01.05.2021)
Get full text
Journal Article
A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium‐Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases
Chen, Michael C., Korth, Christopher C., Harnett, Mark D., Elenko, Eric, Lickliter, Jason D.
Published in Clinical pharmacology in drug development (01.02.2022)
Published in Clinical pharmacology in drug development (01.02.2022)
Get full text
Journal Article
Study of the Population Pharmacokinetic Characteristics of Once-Daily Trospium Chloride 60 mg Extended-Release Capsules in Patients with Overactive Bladder and in Healthy Subjects
Harnett, Mark D., Shipley, James, MacLean, Laura, Schwiderski, Ute, Sandage, Bobby W.
Published in Clinical drug investigation (01.02.2013)
Published in Clinical drug investigation (01.02.2013)
Get full text
Journal Article
Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile x syndrome
Norris, Jordan E, Berry-Kravis, Elizabeth M, Harnett, Mark D, Reines, Scott A, Reese, Melody A, Outterson, Abigail H, Michalak, Claire, Furman, Jeremiah, Gurney, Mark E, Ethridge, Lauren E
Published in Research square (14.06.2024)
Get more information
Published in Research square (14.06.2024)
Journal Article